Ovarian Cancer

Lynparza™ Clinical Trial Demonstrates Survival Benefit in Relapsed Ovarian Cancer (11-9-2016)

AstraZeneca has announced positive results from the Phase III SOLO-2 trial designed to determine the efficacy of LynparzaTM (olaparib) oral therapy for the maintenance treatment of platinum-sensitive relapsed, BRCA-mutated ovarian cancer.1 Results from... Continue Reading

Update on PARP Inhibitors for Ovarian Cancer with BRCA Mutations (10-31-2016)

Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more than 15,000 die of the disease. Treatment for ovarian cancer commonly involves surgery and/or chemotherapy. Researchers continue to study new approaches for... Continue Reading

Tesaro Provides Real Benefit to Ovarian Cancer Patients (10-20-2016)

Patients with platinum-sensitive recurrent ovarian cancer showed significantly improved cancer-free survival with Tesaro (niraparib) in the first clinical trial directly comparing a poly(ADP)-ribose polymerase (PARP) inhibitor with chemotherapy. Tesaro... Continue Reading

FDA Warns Against Ovarian Cancer Screening Tests (10-6-2016)

According to the US Food and Drug Administration (FDA) doctors and their patients should not use certain ovarian cancer screening tests because of inaccurate results. Screening tests are designed to detect cancer in its earliest stages when it is most... Continue Reading

FDA Accepts Priority Review of Rucaparib For The Treatment Of Advanced Mutant BRCA Ovarian Cancer (09-6-2016)

The U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for accelerated approval of rucaparib and granted priority review status to the application for the treatment of advanced ovarian cancer in patients with deleterious... Continue Reading

SGO, ASCO Issue New Guidelines for Ovarian Cancer Treatment (08-22-2016)

A new joint clinical practice guideline from the American Society of Clinical Oncology (ASCO) and the Society of Gynecologic Oncology (SGO) states that neoadjuvant chemotherapy (NACT) is the optimal first-line treatment for some women who have newly diagnosed... Continue Reading

Niraparib Improves Progression-Free Survival in Ovarian Cancer (07-13-2016)

The PARP inhibitor niraparib improves the time to cancer progression among patients with recurrent ovarian cancer when used as maintenance therapy during platinum-based chemotherapy. Each year in the United States, approximately 22,000 women are diagnosed... Continue Reading

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk (05-25-2016)

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing and genetic counseling service, today announced its... Continue Reading

Intraperitoneal Chemotherapy Underused in Ovarian Cancer (09-28-2015)

The use of intraperitoneal (IP) chemotherapy appears to be utilized in fewer than 50% of clinical practices, despite results indicating improved survival with its use in certain patients with ovarian cancer. These results were recently published in the... Continue Reading

Ovarian Cancer survival Influenced by History of Oral Contraceptive Use (09-3-2015)

A history of oral contraceptive use and having at least one child increased longevity by nearly three years in patients diagnosed with ovarian cancer, according to a Roswell Park Cancer Institute (RPCI) study recently published online ahead of print in... Continue Reading

« Previous PageNext Page »